Biotech2050’s Post

Requests for Startups https://lnkd.in/gF4Jgh9w Problems we're excited to help solve: - Building 'Carta for patents' - Biologics targeting intrinsically disordered regions of proteins - Antibodies against GPCRs and ion channels - New ways to use flow cytometry and magnetic sorting for antibody screening - Developing shark antibodies into therapeutics - Antibodies to cross the BBB - Antibody degraders

Today on the Business of Biotech, molecular biologist-turned-Chief Business Officer Neela Patel and academic-turned-founder of newly-formed Bonum Therapeutics John Mulligan, Ph.D. pull back the curtain on Bonum's transition from its predecessor, Good Therapeutics, Inc., which was fueled by a high-profile asset sale to Roche. Listen in as Neela and John share how the deal got done, how Good turned to Bonum, and where the company's taking its platform next. Listen and subscribe here: https://lnkd.in/edtyEWsF

Max Brennan, MSc, this is a great breakdown of the biotech sector's Q1 performance! 🚀 Your insights into the highs of successful IPOs and the lows of industry layoffs are spot-on. Anyone looking to understand the true rollercoaster nature of biotech should definitely give this a read and get in touch with Max Brennan, MSc. Thanks for sharing 👏 #MustRead #BiotechInsights

Check out this video on Thymmune Therapeutics, CEO Stan Wang, MD, PhD gives an overview of the company and science with Jason Carman. Thanks Pillar VC for setting this up!

More #Biotech news today in the neuropsychiatry space: a new company, Neurosterix, emerging with an impressive portfolio of allosteric modulators for certain neurological conditions. Their leading asset is reported to be a selective muscarinic M4 PAM (Positive Allosteric Modulator), in the preclinical stage, as a potential treatment for Schizophrenia. Strategic Landscape Insights: The wave of these relatively newer MOAs to treat Schizophrenia may differentiate, but others (Cerevel Therapeutics; Karuna Therapeutics/ now Bristol Myers Squibb) also have their treatment candidates in play. For certain 'underserved' neuro-conditions, unmet needs exist. The MOA of these allosteric modulators is described as "binding to target receptors outside of active sites, where the natural ligand and traditional drugs operate." This non-competing mechanism allows for "greater selectivity and more precision over the control of biological pathways, potentially delivering improved efficacy and safety." #Biotech #Innovation #Neuropsychiatry #Neuroscience #Healthcare Quotes on MOA from Yahoo Finance via Addex Therapeutics news release.

🚀 𝐁𝐢𝐨𝐭𝐞𝐜𝐡'𝐬 𝐐1 𝐑𝐨𝐥𝐥𝐞𝐫𝐜𝐨𝐚𝐬𝐭𝐞𝐫 𝐑𝐢𝐝𝐞! 🎢 It really has brought mixed emotions! 𝐒𝐨, 𝐢𝐬 𝐭𝐡𝐞 𝐜𝐨𝐦𝐞𝐛𝐚𝐜𝐤 𝐨𝐧 𝐟𝐫𝐨𝐦 𝐚 𝐩𝐨𝐨𝐫 2023? 🤷♂️ 𝐅𝐢𝐫𝐬𝐭 𝐨𝐟𝐟, 𝐭𝐡𝐞 𝐈𝐏𝐎 𝐩𝐚𝐫𝐭𝐲 𝐢𝐬 𝐎𝐍! 🥳 With 8 companies hitting the ground running, 𝐫𝐚𝐤𝐢𝐧𝐠 𝐢𝐧 𝐨𝐯𝐞𝐫 $1.2 𝐛𝐢𝐥𝐥𝐢𝐨𝐧. CG Oncology, Kyverna Therapeutics, and ArriVent Biopharma; all saw their stock prices skyrocket post-IPO. And 𝐥𝐞𝐭’𝐬 𝐧𝐨𝐭 𝐟𝐨𝐫𝐠𝐞𝐭 𝐭𝐡𝐞 𝐩𝐫𝐢𝐯𝐚𝐭𝐞 𝐬𝐞𝐜𝐭𝐨𝐫, swooping in with nearly $4 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐫𝐚𝐢𝐬𝐞𝐝. Mirador Therapeutics, Avenzo Therapeutics, Capstan Therapeutics, Alumis – these are the names to watch out for, boasting some outstanding raises! Unfortunately, there's the other side - 𝐭𝐡𝐞 𝐥𝐚𝐲𝐨𝐟𝐟 𝐬𝐚𝐠𝐚. Yeah, it’s a bit of a heartbreaker 💔, with 57 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 making those tough calls in the last 3 months. Funding droughts are thought to be affecting over 600 venture-backed biotech's and over 1,500 drugs. Of these 600 biotech's, over a third have 𝐧𝐨𝐭 𝐫𝐚𝐢𝐬𝐞𝐝 𝐚𝐧𝐲 𝐜𝐚𝐩𝐢𝐭𝐚𝐥 𝐢𝐧 𝐭𝐡𝐞 𝐥𝐚𝐬𝐭 𝐭𝐡𝐫𝐞𝐞 𝐲𝐞𝐚𝐫𝐬. Tough times that we haven't managed to shake from 2023. So, is the comeback on? 44% 𝐨𝐟 𝐨𝐮𝐫 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐞𝐱𝐞𝐜𝐬 𝐬𝐞𝐞𝐦 𝐭𝐨 𝐭𝐡𝐢𝐧𝐤 𝐬𝐨! 🗨️💡 #BiotechBoomOrBust #InnovationUnleashed #FutureIsNow

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Two SPAC’d biotechs raise additional money as Bihua Chen’s blank check closes $184M IPO: The post-SPAC life isn’t all too great for most biotech companies — or those in other industries, for that matter. But some drug developers that went the blank-check route have found greener pastures in recent months, with two of them announcing large financings this week. Bihua Chen This is amid a second biotech SPAC from Bihua Chen, founder of Cormorant Asset Management. Known as Helix Acquisition Corp. II $HLXB, the SPAC closed a $184 million initial public offering on Wednesday. It will hunt for a biotech or other healthcare business to combine with after Helix I found success with MoonLake Immunotherapeutics. As for the two SPAC’d biotechs, bladder cancer gene therapy company enGene nabbed $200 million in a private placement at a 31% premium to its Tuesday closing price, while non-statin cardiovascular company NewAmsterdam Pharma priced a $175.3 million public offering on Tuesday evening. The raises follow a string of nine-figure financings for public biotechs in recent months, many in advance of or shortly after big data readouts. For enGene and NewAmsterdam, which went public via SPAC in November 2023 and November 2022, respectively, the raises mark a positive in the relatively bleak SPAC universe. The SPAC market “has cratered due to the deep underperformance of pandemic-era de-SPACs,” Oppenheimer bankers wrote in a 2023 review last month. Nine biopharma companies opted for a SPAC in 2023 compared to 21 in 2021, per the report. A few positive signals have emerged for the alternative financing vehicle, lately, though: Chen’s second SPAC (which originally set out for $100 million), and AbbVie’s $8.7 billion plans for Cerevel Therapeutics might serve as the best SPAC combination exit in industry history. enGene The $200 million raise for enGene, which is more than the $138 million in proceeds from its SPAC deal, comes as the Boston and Montreal non-viral gene therapy maker runs a pivotal study of its candidate for certain forms of non-muscle invasive bladder cancer, or NMIBC. The money gives enGene runway into 2027, and investors appeared happy: Shares of the biotech $ENGN skyrocketed 91% before Wednesday’s opening bell. The NMIBC field is riding a wave of momentum. CG Oncology, which is also in Phase III, kicked off the 2024 IPO class with a 95% pop in its first day of trading last month. Meanwhile, ImmunityBio inked up to $320 million in financing last month as it awaits an April PDUFA following an FDA rejection last year. And UroGen, which started its rolling NDA submission last month, raised $120 million on the back of Phase III data last summer. Jason Hanson enGene combined with a SPAC sponsored by Forbion, a European investor that has seen… #lucidquest #genetherapy #celltherapy

We had an exhilarating experience at the 42nd JP Morgan Healthcare Conference in San Francisco last week! The atmosphere was charged with optimism as major pharma-biotech deals unfolded, including billion-dollar acquisitions, particularly in the promising antibody drug conjugate platform with robust clinical data for cancer treatment (check out the link below for more). Notably, NVIDIA made waves by announcing collaborations with Amgen and Recursion, emphasizing the growing role of AI in drug discovery. It's always a privilege engaging with innovative startups and witnessing the relentless pursuit of cutting-edge technologies. The future looks incredibly promising for the intersection of biotech, AI, and groundbreaking technologies! https://lnkd.in/ex7NNXUG

The switch from a CAT T to a CAR M program sets off a whirl of activity. A #celltherapy #biotech re-launches a #CDMO they'd purchased and integrated years before. Everything is fueled by some enlightened #venturecapital, ownership and strategy. Buckle up for one highly interesting (and enlightening) multi-part narrative. Matthias Schroff, Bruce Thompson, Shailesh Maingi, Frank Lis. Inceptor Bio, Kincell Bio, Kineticos Ventures.

Gene&Cell Therapy >> Two SPAC’d biotechs raise additional money as Bihua Chen’s blank check closes $184M IPO: The post-SPAC life isn’t all too great for most biotech companies — or those in other industries, for that matter. But some drug developers that went the blank-check route have found greener pastures in recent months, with two of them announcing large financings this week. Bihua Chen This is amid a second biotech SPAC from Bihua Chen, founder of Cormorant Asset Management. Known as Helix Acquisition Corp. II $HLXB, the SPAC closed a $184 million initial public offering on Wednesday. It will hunt for a biotech or other healthcare business to combine with after Helix I found success with MoonLake Immunotherapeutics. As for the two SPAC’d biotechs, bladder cancer gene therapy company enGene nabbed $200 million in a private placement at a 31% premium to its Tuesday closing price, while non-statin cardiovascular company NewAmsterdam Pharma priced a $175.3 million public offering on Tuesday evening. The raises follow a string of nine-figure financings for public biotechs in recent months, many in advance of or shortly after big data readouts. For enGene and NewAmsterdam, which went public via SPAC in November 2023 and November 2022, respectively, the raises mark a positive in the relatively bleak SPAC universe. The SPAC market “has cratered due to the deep underperformance of pandemic-era de-SPACs,” Oppenheimer bankers wrote in a 2023 review last month. Nine biopharma companies opted for a SPAC in 2023 compared to 21 in 2021, per the report. A few positive signals have emerged for the alternative financing vehicle, lately, though: Chen’s second SPAC (which originally set out for $100 million), and AbbVie’s $8.7 billion plans for Cerevel Therapeutics might serve as the best SPAC combination exit in industry history. enGene The $200 million raise for enGene, which is more than the $138 million in proceeds from its SPAC deal, comes as the Boston and Montreal non-viral gene therapy maker runs a pivotal study of its candidate for certain forms of non-muscle invasive bladder cancer, or NMIBC. The money gives enGene runway into 2027, and investors appeared happy: Shares of the biotech $ENGN skyrocketed 91% before Wednesday’s opening bell. The NMIBC field is riding a wave of momentum. CG Oncology, which is also in Phase III, kicked off the 2024 IPO class with a 95% pop in its first day of trading last month. Meanwhile, ImmunityBio inked up to $320 million in financing last month as it awaits an April PDUFA following an FDA rejection last year. And UroGen, which started its rolling NDA submission last month, raised $120 million on the back of Phase III data last summer. Jason Hanson enGene combined with a SPAC sponsored by Forbion, a European investor that has seen recent M&A successes with Aiolos Bio, Inversago… #lucidquest #genetherapy #celltherapy